Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.00
Bid: 32.00
Ask: 32.90
Change: -0.25 (-0.76%)
Spread: 0.90 (2.813%)
Open: 32.20
High: 32.20
Low: 32.00
Prev. Close: 32.70
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - International Brand Licensing plc

18 Jun 2010 15:03

RNS Number : 8898N
AIM
18 June 2010
 



 

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

 

International Brand Licensing plc (to be renamed EKF Diagnostics Holdings plc)

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

 

14 Kinnerton Place South, London SW1X 8EH

COUNTRY OF INCORPORATION:

England and Wales

 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.iblplc.com

 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

The Admission is the result of a reverse takeover through the acquisition by International Brand Licensing plc of EKF-diagnostic GmbH ("EKF").

 

The existing business of International Brand Licensing plc is focused on exploiting a portfolio of sports and lifestyle brands, trade names and logos by granting licences to third parties allowing them to manufacture, market and sell products in pre determined territories across the world. The Directors intend to dispose of the company's licensing business as opportunities arise over the coming months.

 

The EKF Group comprises established businesses with operations in Germany, Poland and Russia which are focused on the design, development, manufacture and selling of diagnostic instruments and reagents. EKF's products and devices are designed to meet the needs of smaller professional clinical and research laboratories, doctor's offices, sports clinics and athletic testing sites.

 

 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

 

A total of 100,435,653 new ordinary shares of 1 pence each and re admission of 41,991,653 existng ordinary shares of 1 pence each

 

The shares are expected to be admitted on three separate dates:

 

First admission (first tranche placing shares): 10,666,665 new ordinary shares of 1 pence each

 

Second admission (second tranche placing shares): 25,499,998 new ordinary shares of 1 pence each

 

Third admission (third tranche placing shares and re admission of existing ordinary shares): 64,268,990 new ordinary shares of 1 pence each and re admission of all existing ordinary shares

 

 

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

£ 15.06 million

Market Capitalisation expected to be £21.36 million on Admission

 

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

 

29.94%

 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED:

N/a

 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Directors

David Eric Evans (Non-Executive Chairman)

Julian Huw Baines (Chief Executive Officer)

Paul Andrew Peter Foulger (Finance Director)

Adam Reynolds (Non-Executive Director)

Gordon James Hall (Non-Executive Director)

Dr Kevin William Wilson (Non-Executive Director)

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Name

 

 

 

 

 

 

 

Legal & General

 

Octopus Asset Management

 

Hargreave Hale

 

Ignis Asset Management

 

HSBC Global Custody Nominee (UK) Ltd BH01 883031

 

Newedge Group

SA 2093110

 

JM Finn Nominees Ltd

 

Lance Yates Esq (Estate of)

 

Pershing Nominees Ltd

BFCLT

 

Julian Baines

 

The Bank of New York (Nominees) Limited

 

James Capel (Nominees) Limited

 

Number of Ordinary Shares prior to Admission

 

 

 

 

-

 

-

 

-

 

-

 

 

7,153,693

 

 

5,590,000

 

 

3,026,403

 

1,708,480

 

1,521,243

 

 

1,357,127

 

1,318,000

 

 

1,274,472

 

 

% of the Issued Ordinary Share Capital prior to Admission

 

-

 

-

 

-

 

-

 

17.04

 

 

13.31

 

 

7.21

 

4.07

 

3.62

 

 

3.23

 

3.14

 

 

3.04

 

 

Number of Ordinary Shares following Admission

 

 

 

22,000,000

 

15,000,000

 

10,666,666

 

8,333,333

 

 

7,153,693

 

 

5,590,000

 

 

3,026,403

 

1,708,480

 

1,521,243

 

 

1,357,127

 

1,318,000

 

 

1,274,472

 

 

% of issued Share Capital following Admission

 

 

15.45

 

10.53

 

7.49

 

5.85

 

 

5.02

 

 

3.92

 

 

2.12

 

1.20

 

1.07

 

 

0.95

 

0.93

 

 

0.89

 

 

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

N/a

 

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

 

(i) 31 December

(ii) 31 December 2009 (in relation to EKF); financial information in relation to International Brand Licensing plc has been omitted in accordance with Rule 28

(iii) 30 September 2010, 30 June 2011, 30 September 2011

 

EXPECTED ADMISSION DATE:

7 July 2010

 

NAME AND ADDRESS OF NOMINATED ADVISER:

Zeus Capital Limited 3 Ralli Courts West Riverside Manchester M3 5FT

 

NAME AND ADDRESS OF BROKER:

Joint Brokers:

Zeus Capital Limited 3 Ralli Courts West Riverside Manchester M3 5FT

 

Matrix Corporate Capital LLP

One Vine Street

London

W1J 0AH

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

www.iblplc.com The admission document contains full details about the company and the admission of its securities.

DATE OF NOTIFICATION:

18 June 2010

 

NEW/ UPDATE:

New

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PAAEALKPFEAEEFF
Date   Source Headline
7th Apr 20207:00 amRNSFinal Results
24th Mar 20207:00 amRNSDetailed trading review including COVID-19 update
20th Mar 20207:00 amRNSInvestor results briefing update
4th Mar 20207:00 amRNSNotice of Results
24th Feb 20201:56 pmRNSHolding(s) in Company
29th Jan 20207:00 amRNSTrading update
6th Nov 201912:14 pmRNSTrading update and performance bonuses
10th Sep 20197:00 amRNSHalf-year Report
10th Sep 20197:00 amRNSPreferred Partner Arrangement with Mount Sinai
21st Aug 20197:00 amRNSNotice of Results
8th Aug 20194:40 pmRNSSecond Price Monitoring Extn
8th Aug 20194:35 pmRNSPrice Monitoring Extension
15th Jul 20197:00 amRNSTrading update
11th Jun 20192:15 pmRNSCancellation of share options
7th Jun 20194:30 pmRNSHolding(s) in Company
28th May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 201911:21 amRNSResult of AGM
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
25th Apr 20197:00 amRNSPosting of AR & Accounts and Notice of AGM
13th Mar 20197:00 amRNSFinal Results
8th Mar 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUS FDA approval for Quo-Test analyser
22nd Jan 20197:00 amRNSUpdate on McKesson US distribution agreement
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
16th Jan 20197:00 amRNSTrading update
20th Dec 20187:00 amRNSUpdate regarding planned change of NOMAD
19th Dec 20184:56 pmRNSPDMR dealing
7th Dec 20183:15 pmRNSPurchase of own shares and PDMR Dealing
30th Nov 20182:35 pmRNSTotal Voting Rights
22nd Nov 20185:13 pmRNSPurchase of own shares and PDMR Dealing
21st Nov 20182:08 pmRNSPurchase of own shares and PDMR Dealing
20th Nov 20185:18 pmRNSPurchase of own shares and PDMR Dealing
14th Nov 20182:20 pmRNSShare Buy-Back
9th Nov 20181:48 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings
2nd Nov 20188:00 amRNSSchedule 1 update - Renalytix AI plc
1st Nov 20185:30 pmRNSUpdate regarding AIM admission of RenalytixAI
31st Oct 20186:00 pmRNSResult of RO by RenalytixAI & Fundraising Update
23rd Oct 20182:00 pmRNSSchedule One Update - Renalytix AI plc
23rd Oct 201811:01 amRNSUpdate to distribution timetable
22nd Oct 20185:23 pmRNSApproval of distribution of shares in RenalytixAI
19th Oct 201812:10 pmRNSResult of General Meeting
19th Oct 201811:00 amRNSSchedule One - Renalytix AI plc
12th Oct 20187:00 amRNSInvestor presentation
11th Oct 20186:03 pmRNSLaunch of Restricted Offer by Renalytix AI plc
11th Oct 20185:21 pmRNSFundraising and AIM admission of Renalytix AI plc
11th Oct 20184:01 pmRNSFundraising and AIM admission of Renalytix AI plc
27th Sep 201810:15 amRNSNotice of GM
19th Sep 20187:00 amRNSHalf-year Report
17th Sep 201812:21 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.